Salbutamol dry-powder inhalation - Teva Pharmaceutical Industries

Drug Profile

Salbutamol dry-powder inhalation - Teva Pharmaceutical Industries

Alternative Names: ABS eMDPI; Airmax Salamol; Albuterol DPI - Teva; Albuterol dry-powder inhalation - Teva; Albuterol eMDPI; Albuterol MDPI; Albuterol Spiromax; Albuterol sulfate - Teva; ProAir RespiClick; Salbutamol DPI - Teva

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IVAX Corporation
  • Developer IVAX Corporation; Teva Pharmaceutical Industries
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Phenethylamines; Small molecules; Tocolytics
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Exercise-induced asthma
  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 28 Sep 2017 Phase-III clinical trials in Chronic obstructive pulmonary disease in USA (Inhalation) (NCT03256695)
  • 28 Aug 2017 Teva Pharmaceutical plans a phase III trial for Chronic obstructive pulmonary disease (NCT03256695)
  • 13 Feb 2017 Teva initiates enrolment in a phase III trial for Asthma in USA (NCT02969408)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top